China’s National Health Commission (NHC) has launched its fourth comprehensive catalog of reference brand-name drugs, marking a significant advancement in the nation’s healthcare strategy. Released on January 5, 2026, this initiative specifically targets the development of high-quality generic alternatives to address critical clinical gaps across multiple medical specialties.
The newly published catalog, developed through collaboration between the NHC and three additional government agencies, features 21 innovative pharmaceutical products spanning oncology, neurology, reproductive medicine, and diagnostic imaging. The selection process prioritized medications demonstrating novel therapeutic mechanisms and targets, including groundbreaking treatments such as difelikefalin for chronic kidney disease-associated pruritus and four radiopharmaceutical therapies currently unavailable in domestic markets.
Notably, the catalog incorporates internationally recognized first-line treatments like suvorexant for insomnia management, which demonstrates efficacy in sleep initiation and maintenance while reducing daytime impairment. In alignment with national population policies, the list also includes advanced reproductive health formulations designed as gels and suppositories to minimize adverse reactions during assisted reproduction procedures.
The catalog further emphasizes medicines with established clinical utility within China’s healthcare system, such as deflazacort for managing Duchenne muscular dystrophy. Since initiating this program in 2019, Chinese health authorities have consistently released these catalogs to accelerate the availability of affordable, therapeutically equivalent generic medications, thereby enhancing treatment accessibility while maintaining pharmaceutical quality standards.